AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Omada Health
Video analysis: OMDA
All videosNo video analysis for this stock yet. Request one from our team.
News: OMDA
Omada Health, Inc. (OMDA) Analyst/Investor Day Transcript
Omada Health, Inc. (OMDA) Analyst/Investor Day Transcript
Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day
SAN FRANCISCO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, will present its long-term financial targets at the company's inaugural Investor Day, being held today at the Four Seasons Hotel in New York, New York.
Independent Model Estimates Up To $11,142 in Gross Medical Cost Savings Per Member Over Five Years for Omada's GLP-1 Program
SAN FRANCISCO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, announced a new, independent cost savings model that examined the measurable clinical and economic value of Omada's GLP-1 program.1 GlobalData , a data analytics and consulting company, recently published a report estimating greater disease reduction and higher cumulative cost savings with Omada's GLP-1 solutions compared to standard care.
Insider Alert: Omada Health CEO Sean Duffy Sells 31,457 Shares
Traded 31,457 shares with a transaction value of ~$735,150 based on a weighted average price of $23.37 per share. The activity involved shares equal to 2% of the total equity stake held before the filing, including direct transactions equal to 8% of the prior direct position.
Omada Health, Inc. (NASDAQ:OMDA) Receives $26.50 Average PT from Brokerages
Shares of Omada Health, Inc. (NASDAQ: OMDA - Get Free Report) have been given an average rating of "Moderate Buy" by the fourteen analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have issued a buy recommendation
2,222,074 Shares in Omada Health, Inc. $OMDA Bought by BlackRock Inc.
BlackRock Inc. bought a new position in shares of Omada Health, Inc. (NASDAQ: OMDA) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,222,074 shares of the company's stock, valued at approximately $48,775,000. BlackRock Inc. owned approximately 3.74%
Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
Omada Health (OMDA) delivered strong Q2 results, with 43% revenue growth, margin expansion, and positive adj. EBITDA, reinforcing my buy rating. OMDA's product expansion, especially in diabetes and hypertension, is driving higher revenue per member and improving customer-lifetime-value through multi-program adoption. Channel partnerships with PBMs and health plans are lowering CAC, supporting scalable growth and better unit economics, while AI initiatives further enhance operational leverage.
Omada Health Touts Record Q2 as GLP-1 Demand Fuels Growth Strategy
Omada Health NASDAQ: OMDA highlighted record second-quarter revenue and margin performance at the Canaccord Genuity Growth Conference, while outlining its strategy to expand across cardiometabolic conditions, deepen channel partnerships and use GLP-1-related demand to broaden customer relationships.
